Tissue Regenix Share Discussion Threads

[rayrac] 13/6/2016 16:06

So why the fall of 7%+?

News on the way, or a rival in the way?

[channel pirate] 13/6/2016 12:47

Thanks bamboo2, will sit on the fence for a bit longer. Should we have news soon, then I have a nice chunk (for me anyway) of shares in the portfolio already.

[bamboo2] 13/6/2016 11:35

cp, chart does suggest wait until RSI is less overbought.

News, however, could come at any time.

The application for the meniscus CE mark is likely to be made next month and this could co-incide with some interim results from the trial.

[channel pirate] 13/6/2016 09:55

I now have some funds to ADD to my holding here, but have this feeling we may drop (retreat) some more yet.

Not being a chartist etc, then maybe someone who is can offer their opinion !!

[bamboo2] 08/6/2016 15:15

Neat presentation,

[bamboo2] 08/6/2016 08:50

LEEDS, England--(BUSINESS WIRE)--Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”) the regenerative medical devices company announces that CEO, Antony Odell will present a corporate overview at the Jefferies Healthcare Conference in New York on Tuesday 7th June at 13:30 EDT.

The UK-based company utilises patented dCELL® Technology which addresses clinical needs in wound care, orthopaedic and cardiac applications. The Group commercialised DermaPure®, addressing chronic and acute wounds under Tissue Regenix Wound Care Inc. in 2014, and recently established a further US subsidiary, Tissue Regenix Orthopedics, Inc. earlier in 2016 to bring its OrthoPure™ products to the US market.

The presentation will be available on the companies website following the presentation

[swiss paul] 02/6/2016 21:00

when I see sales improve - then I will be happy but at the moment I am not impressed

[callmebwana] 01/6/2016 23:50

I see everybody is happy. Good so we should be.

[rayrac] 01/6/2016 09:23

Connections connections. Ability ability.

[bamboo2] 01/6/2016 09:00

01 June 2016

Tissue Regenix Group plc

New appointment adds clinical expertise to Board

Leeds, 1 June, 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces that it has appointed Professor Shervanthi Homer - Vanniasinkam as a Non- Executive Director with immediate effect.

Professor Homer-Vanniasinkam is a respected Consultant Vascular Surgeon who holds a number of appointments at medical and academic institutions across the country, and is regularly invited to lecture at prestigious establishments across the world. She was recently appointed to the First Chair of Engineering and Surgery at University College London, and currently holds positions which include Clinical Sub - Dean, University of Leeds Medical School and Professor of Surgery University of Warwick Medical School and University Hospitals Coventry and Warwickshire. Professor Homer-Vanniasinkam has been acting as a clinical advisor to the Group for a number of years and has extensive experience of medical research, development and innovation.

John Samuel, Chairman of Tissue Regenix Group commented: "We welcome the appointment of Shervanthi as a Non- Executive Director, having supported Tissue Regenix in an advisory role for a number of years. With a strong commercially - focussed Board we feel it imperative to match this with clinical expertise as the Group continues to grow and bring dCELL(R) to the market. The appointment of Shervanthi at this time highlights the continued momentum of Tissue Regenix as we expand further into the US marketplace and bring human tissue applications to Europe."

Further Information:

Full Name: Shervanthi Homer- Vanniasinkam

Age: 58

Other Corporate Board positions: N/A

Present Appointments:

Consultant Vascular Surgeon, Leeds Vascular Institute, Leeds General Infirmary

Clinical Sub-Dean, University of Leeds Medical School & Director of EXSEL@Leeds

Professor of Surgery (Founding), University of Warwick Medical School &

University Hospitals Coventry and Warwickshire

Professor of Engineering and Surgery, University College London

[rayrac] 01/6/2016 07:28

Shervanthi Homer- Vanniasinkam

What a superb appointment to the board.

[bamboo2] 31/5/2016 15:37

Meniscus trial submits final data for CE mark soon after July 12th. Hope to get some news regarding initial outcomes by then.

[luminoso] 31/5/2016 14:13

Mmm, the quieter the board, the better the share price, it seems !
If it breaks 22p, can't see much holding us back til 30p.
Edit - Doh ! Spoke too soon !

[luminoso] 27/5/2016 15:04

I certainly am !

[channel pirate] 27/5/2016 14:44

(250K Buy) Probably Mr Woodford is having to pick up smaller amounts now as pi's are feeling more confident and hanging on to what they have got for the journey ahead ??

[luminoso] 27/5/2016 14:33

Was that a crunch I heard ? :-) 250k buy.

[luminoso] 27/5/2016 12:24

Some good buying again today. Might be building some momentum now. Another bite from Woodford would not go amiss.

[luminoso] 26/5/2016 08:29

Another mention here :-

[bamboo2] 23/5/2016 20:21

Published on 22 May 2016



The power of dCELL® technology.
dCELL® technology offers a unique approach to regenerative medicine. The dCELL® process is gentle, efficient,effective — and powerful. It results in allograft and xenograft tissue matrices that are up to 99% DNA free, but retains the tissues’ native growth factors, collagenand elastin throughout the process. It can be applied to both donated human tissues (allografts), or animal tissues (xenografts).

The dCELL® process removes DNA and cellular material from donor tissues, through a series of gentle washes, leaving an intact acellular matrix upon which the patient’s cells can repopulate and colonise, creating new, like - for - like tissue, which is recognised and accepted by the body, significantly reducing the risk of rejection. dCELL® technology provides an enhanced healing environment, in terms of both natural, tissue-specific physical structure and biochemical properties.
Tissue treated with dCELL® technology gives the patient a receptive scaffold that supports cell migration following implantation, while maintaining appropriate tissue strength. Once re-population is complete, the regenerated tissue is effectively a natural part of the patient’s own body. The potential applications of dCELL® are diverse and currently Tissue Regenix is focusing on addressing complex and unmet needs in three core clinical areas:
Wound care, orthopaedics and cardiac.

[bamboo2] 23/5/2016 20:19

Published on 22 May 2016



Tissue Regenix OrthoPure - ACL Sports Injuries by Peter Hamer

[bamboo2] 23/5/2016 20:13

Published on 22 May 2016



Gabriely is twelve years old. Today she enjoys participating in sport and other physical activities as do most children of her age. However, this has not always been the case. When Gabriely was born she was found to have aortic stenosis and at just five days old underwent her first cardiac surgery. Unfortunately, this initial procedure was unsuccessful and thirty days later Gabriely required further heart valve surgery, having two major surgical interventions before she was even six weeks old. Throughout her early years she required carefully monitored medication, but even with that Gabriely was unable to participate in normal childhood activities with her friends, and so when she was three years old the decision was made that she needed to have a heart valve replacement. Although at the time there were several therapeutic options available, for a young girl, the potential drawbacks of these could impact the rest of her life. As a growing child she could well need to undergo further major cardiac surgery in the future, and would require anti-coagulant drugs for the rest of her life, both meaning that it would also be unlikely that she would be able to have her own children.Then the family heard about dCELL®.
Gabriely received a dCELL® valve in October 2007 and has since had no need for medication or reoperation; she is now only required to have a follow up appointment once a year. Thankfully, nine years later Gabriely is now living the life of a normal twelve year old girl to the full, enjoying ballet and playing with her friends.
Gabriely and her family now look forward to a positive future. Gabriely hopes that the she will become a paediatrician, so that she can help children in similar situations.
Thanks to dCELL®, that dream could very well become a reality.

[rayrac] 23/5/2016 11:43

I agree with you Igbert...all a bit hazy, ie, all as per expectations,ie, expectations of a loss, maybe an increased loss. But heyho, it is a start up?

[igbertsponk] 23/5/2016 10:11

Yes I read it, but would have preferred to read something along the lines of "we have entered the new year with sales accelerating well and already have secured revenues of $x.xm".